Evidence map›Paper›PMID 34225671›Full record

ArticleBMC nephrology2021

Hepatic cysteine sulphinic acid decarboxylase depletion and defective taurine metabolism in a rat partial nephrectomy model of chronic kidney disease.

Nima Abbasian, Maryam Ghaderi-Najafabadi, Emma Watson, Jeremy Brown, Li Yu Si, Debbie Bursnall, Izabella Pawluczyk, Anne-Marie Seymour, Alan Bevington

Open access · goldAbstract read
In one paragraph

Article in BMC nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Nima AbbasianDepartment of Respiratory Sciences, University of Leicester, Leicester, LE1 7RH, UK. Abbasian.n.174@gmail.com.ORCID 0000-0002-6906-2563
Maryam Ghaderi-NajafabadiDepartment of Respiratory Sciences, University of Leicester, Leicester, LE1 7RH, UK.
Emma WatsonDepartment of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Jeremy BrownDepartment of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Li Yu SiDepartment of Respiratory Sciences, University of Leicester, Leicester, LE1 7RH, UK.
Debbie BursnallDivision of Biomedical Services, University of Leicester, Leicester, UK.
Izabella PawluczykDepartment of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Anne-Marie SeymourSchool of Life Sciences (Biomedical), University of Hull, Hull, UK.
Alan BevingtonDepartment of Respiratory Sciences, University of Leicester, Leicester, LE1 7RH, UK. 57rrd1955@gmail.com.
University of Leicester · GBUniversity of Hertfordshire · GBUniversity of Hull · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTaurine depletion occurs in patients with end-stage chronic kidney disease (CKD). In contrast, in the absence of CKD, plasma taurine is reported to increase following dietary L-glutamine supplementation. This study tested the hypothesis that taurine biosynthesis decreases in a rat CKD model, but is rectified by L-glutamine supplementation.

methodsCKD was induced by partial nephrectomy in male Sprague-Dawley rats, followed 2 weeks later by 2 weeks of 12% w/w L-glutamine supplemented diet (designated NxT) or control diet (NxC). Sham-operated control rats (S) received control diet.

resultsTaurine concentration in plasma, liver and skeletal muscle was not depleted, but steady-state urinary taurine excretion (a measure of whole-body taurine biosynthesis) was strongly suppressed (28.3 ± 8.7 in NxC rats versus 78.5 ± 7.6 μmol/24 h in S, P < 0.05), accompanied by reduced taurine clearance (NxC 0.14 ± 0.05 versus 0.70 ± 0.11 ml/min/Kg body weight in S, P < 0.05). Hepatic expression of mRNAs encoding key enzymes of taurine biosynthesis (cysteine sulphinic acid decarboxylase (CSAD) and cysteine dioxygenase (CDO)) showed no statistically significant response to CKD (mean relative expression of CSAD and CDO in NxC versus S was 0.91 ± 0.18 and 0.87 ± 0.14 respectively). Expression of CDO protein was also unaffected. However, CSAD protein decreased strongly in NxC livers (45.0 ± 16.8% of that in S livers, P < 0.005). L-glutamine supplementation failed to rectify taurine biosynthesis or CSAD protein expression, but worsened CKD (proteinuria in NxT 12.5 ± 1.2 versus 6.7 ± 1.5 mg/24 h in NxC, P < 0.05).

conclusionIn CKD, hepatic CSAD is depleted and taurine biosynthesis impaired. This is important in view of taurine's reported protective effect against cardio-vascular disease - the leading cause of death in human CKD.

Indexed as

Dietary SupplementsAnimalsCarboxy-LyasesCysteine DioxygenaseDisease Models, AnimalGlutamineHumansLiverMaleMuscle, SkeletalNephrectomyProteinuriaRatsRats, Sprague-DawleyRenal Insufficiency, ChronicRNA, MessengerCarboxy-LyasesCysteine DioxygenaseGlutamineRNA, Messengersulfoalanine decarboxylaseTaurineChronic kidney diseaseCysteine sulphinic acid decarboxylaseL-glutamineSulphinoalanine decarboxylaseTaurine

Identifiers

PMID34225671
PMCPMC8256558
OpenAlexW3179430554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.